Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Provided By PR Newswire
Last update: Jul 24, 2025
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment
Read more at prnewswire.comNASDAQ:ATRA (9/3/2025, 1:42:58 PM)
12.35
+0.01 (+0.08%)
Find more stocks in the Stock Screener
